128 related articles for article (PubMed ID: 23155506)
1. FDA approves new 4-drug once-a-day HIV treatment.
AIDS Policy Law; 2012 Oct; 27(11):1. PubMed ID: 23155506
[No Abstract] [Full Text] [Related]
2. Tenofovir alafenamide for HIV infection: is less more?
Wyatt C; Baeten JM
Lancet; 2015 Jun; 385(9987):2559-60. PubMed ID: 25890672
[No Abstract] [Full Text] [Related]
3. Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Fulco PP; Ayala-Sims VA
Am J Health Syst Pharm; 2014 May; 71(10):784, 786. PubMed ID: 24780482
[No Abstract] [Full Text] [Related]
4. [ First integrase inhibitor based single tablet regimen].
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():20-1. PubMed ID: 23961647
[No Abstract] [Full Text] [Related]
5. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
7. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
8. Single-tablet, once-daily treatment regimens for HIV.
Sawyer JR; Ma Q; Hsiao CB
Lancet Infect Dis; 2014 Apr; 14(4):265-7. PubMed ID: 24670622
[No Abstract] [Full Text] [Related]
9. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
10. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
11. A 4-drug combination (Stribild) for HIV.
Med Lett Drugs Ther; 2012 Nov; 54(1404):95-6. PubMed ID: 23183388
[No Abstract] [Full Text] [Related]
12. [A single tablet against HIV: new combination preparation improves therapy].
Pommer P
Dtsch Med Wochenschr; 2012 Aug; 137(34-35):1673. PubMed ID: 22893044
[No Abstract] [Full Text] [Related]
13. FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
AIDS Alert; 2009 Oct; 24(10):119-20. PubMed ID: 20034141
[No Abstract] [Full Text] [Related]
14. Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Prescrire Int; 2013 Oct; 22(142):233-5. PubMed ID: 24298581
[TBL] [Abstract][Full Text] [Related]
15. Recent FDA approvals and changes.
AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
[No Abstract] [Full Text] [Related]
16. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
Lampiris HW
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):13-20. PubMed ID: 22149610
[TBL] [Abstract][Full Text] [Related]
17. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
Manzardo C; Gatell JM
AIDS Rev; 2014; 16(1):35-42. PubMed ID: 24584107
[TBL] [Abstract][Full Text] [Related]
18. Drug updates and approvals: 2012 in review.
Belavic JM
Nurse Pract; 2013 Feb; 38(2):24-42; quiz 42-3. PubMed ID: 23295643
[TBL] [Abstract][Full Text] [Related]
19. Stribild: a review of component characteristics and combination drug efficacy.
Murrell DE; Moorman JP; Harirforoosh S
Eur Rev Med Pharmacol Sci; 2015; 19(5):904-14. PubMed ID: 25807445
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Gallant JE; Koenig E; Andrade-Villanueva JF; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Rizzardini G; Fehr J; Liu HC; Abram ME; Cao H; Szwarcberg J
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):338-40. PubMed ID: 26181707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
